Showing 3821-3830 of 5314 results for "".
- Risk-Guided Screening Enhances Early Skin Cancer ID in Transplant Cohorthttps://practicaldermatology.com/news/risk-guided-screening-enhances-early-skin-cancer-id-in-transplant-cohort/2483972/A risk-based skin cancer surveillance strategy was associated with improved early detection rates among solid organ transplant (SOT) recipients, according to findings from a recent retrospective cohort analysis of the implementation of the KP-SUNTRAC program across K
- Study: Epidermal Mitochondrial Loss Linked to Skin Aging and Fat Gainhttps://practicaldermatology.com/news/study-epidermal-mitochondrial-loss-linked-to-skin-aging-and-fat-gain/2483941/A new study published in the Journal of Investigative Dermatology suggests mitochondrial decline in epidermal keratinocytes plays a central role in skin aging and may also contribute to age-related obesity.
- Dr. Karan Lal Shares 'Recipe' for Prescribing GLP-1shttps://practicaldermatology.com/news/dr-karan-lal-shares-recipe-for-prescribing-glp-1s/2483869/The increasingly understood relevance of weight-loss drugs to inflammatory skin conditions was a hot topic at the Skin of Color Update in New York, New York, and Karan Lal, DO, FAAD, shared his “recipe” for addressing it with patients. Dr. Lal first checks for prior diagnoses of diabetes m
- Roflumilast 0.05% Gains FDA Approval for Children 2-5 with ADhttps://practicaldermatology.com/news/roflumilast-005-gains-fda-approval-for-children-2-5-with-ad/2483862/The US Food and Drug Administration (FDA) has approved roflumilast cream 0.05% (Zoryve®, Arcutis Biotherapeutics) for the treatment of mild-to-moderate atopic dermatitis (AD) in children 2 to 5 years old. This once-daily topical phosphodiesterase-4 (PDE4) inhibitor
- FDA Clears IND for Rubedo’s GPX4 Modulator in Actinic Keratosishttps://practicaldermatology.com/news/fda-clears-ind-for-rubedos-gpx4-modulator-in-actinic-keratosis/2483388/Rubedo Life Sciences has received FDA clearance for a second Investigational New Drug (IND) application for its lead compound RLS-1496, enabling a Phase 1b/2a trial in patients with actinic keratosis to begin in Q4 2025. Accordi
- Arcutis Seeks FDA Greenlight to Expand ZORYVE for Children Under 6https://practicaldermatology.com/news/arcutis-seeks-fda-greenlight-to-expand-zoryve-for-children-under-6/2483230/Arcutis Biotherapeutics has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in children aged 2 to 5, according to
- Dual-Wavelength Laser Caps Gain Clinical Validation for Hair Density Gainshttps://practicaldermatology.com/news/dual-wavelength-laser-caps-gain-clinical-validation-for-hair-density-gains/2476121/KeraFactor announced that it will be spotlighting its dermatologist-developed hair health solutions this August in recognition of National Hair Loss Awareness Month, according to a news release from the manufacturer. The bran
- FDA Greenlights First Treatment for Chronic Hand Eczema in Adultshttps://practicaldermatology.com/news/fda-approves-first-treatment-for-chronic-hand-eczema-in-adults/2475816/The US Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream, making it the first and only treatment approved for adults with moderate-to-severe chronic hand eczema (CHE) who are unresponsive to topical corticosteroids or for those unsuitabl
- OSkin Study: Genetic Risk and Nevus Count Stronger Predictors for NAMhttps://practicaldermatology.com/news/genetic-risk-and-nevus-count-stronger-predictors-for-nam-study-finds/2475635/High nevus density and polygenic susceptibility are more strongly associated with nevus-associated melanoma (NAM) than with de novo melanoma, according to results from a new large-scale, population-based cohort study. The QSk
- Hands On: Practical Tips for Diagnosing and Treating Chronic Hand Eczemahttps://practicaldermatology.com/news/hands-on-practical-tips-for-diagnosing-and-treating-chronic-hand-eczema/2475415/Despite its small body surface area involvement, chronic hand eczema (CHE) represents a significant dermatologic and socioeconomic burden. In a recent session on chronic hand eczema (CHE) Socity of Dermatology Physician Associates (SDPA) 2025 Summer Conference given by Adam Friedman, MD, FAAD, he